El interés en corto de Tactile Systems Tech da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Tactile Systems Tech. Los datos de interés en corto se actualizan cada dos semanas.

Tactile Systems Tech (NASDAQ:TCMD) Bolsa, Informe de interés en corto

Tactile Systems Tech

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Technology Inc

BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $41.505 million which missed the analyst consensus estimate of $46.030 million by 9.83 percent. This is a 22.12 percent increase over sales of $33.988 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

BBAI

BigBear.ai Hldgs Q3 2024 GAAP EPS $(0.05) Beats $(0.07) Estimate, Sales $41.505M Miss $46.030M Estimate

Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.65 by 27.69 percent. The company reported quarterly sales of $625.71 million which beat the analyst consensus estimate of $603.93 million by 3.61 percent. This is a 63.10 percent increase over sales of $383.64 million the same period last year.

GMED

Globus Medical Q3 2024 Adj EPS $0.83 Beats $0.65 Estimate, Sales $625.71M Beat $603.93M Estimate

WIIM

B&G Foods shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 net sales guidance below estimates.

Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.
Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE&#x2122; (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018. Pursuant to the license agreement, Acadia is required to pay Neuren one-third of the net proceeds.
Acadia plans to invest proceeds from the sale of the PRV to support its commercial operations, R&amp;D programs in central nervous system and rare disease, and future business development.
The transaction is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Jefferies LLC acted as financial advisor to Acadia on this transaction.

Asset Sales

ACAD

Acadia Pharmaceuticals Enters Into An Agreement To Sell Its Rare Pediatric Disease Priority Review Voucher For $150M

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) reported quarterly earnings of $0.14 per share. The company reported quarterly sales of $37.640 million which missed the analyst consensus estimate of $42.000 million by 10.38 percent. This is a 649.35 percent increase over sales of $5.023 million the same period last year.

GIFI

Gulf Island Fabrication Q3 2024 GAAP EPS $0.14, Sales $37.640M Miss $42.000M Estimate

Ternium Q3 2024 EPADS $0.16, Sales $4.480B Beat $4.446B Estimate

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC
Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 39th&nbsp;Annual Meeting in Houston, November 6-10.

Biotech

General

PSTX

Poseida Therapeutics To Present Clinical And Preclinical Data On Investigational Allogeneic CAR-T Cell Therapies At SITC 2024 And ASH 2024

Guidance

QLYS

Qualys Expects Q4 Adj EPS Of $1.28 - $1.38 (Est $1.28), Revenues Of $154.5M - $157.5M (Est $154.059M)

MGNX

MacroGenics shares are trading higher after the company reported better-than-expected Q3 financial results.

International Flavors & Fragrances Sees FY24 Sales $11.3B-$11.4B Vs $11.288B Est.

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real World Study Compared Over 150,000 Adult &amp; Pediatric Patients – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor Associated with Fewer Adverse Drug Reactions – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor also Improved Healthcare Utilization –
NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac.
This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ketorolac adult patients were selected and compared for ADRs and subsequent healthcare resource utilization, which includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis.
Key findings reveal that, in adults, Caldolor was associated with a 45% reduction in renal dysfunction (p&lt;0.001) and a 78% decrease in hematuria rates (p&lt;0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications as well as reduced headaches, nausea and abdominal pain. Among pediatric patients, the results showed Caldolor was associated with a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals supporting clinical significance.
Caldolor also demonstrated a positive impact on healthcare resource utilization (HCRU) when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children.

CPIX

Cumberland Pharmaceuticals Announces The Publication Of New Real-World Outcomes Research Demonstrating The Safety And Healthcare Resource Advantages Of Its Caldolor (Ibuprofen) Injection Over Ketorolac In Both Adult And Pediatric Populations

AVNW

Aviat Networks shares are trading lower after the company reported worse-than-expected Q1 financial results and lowered its FY25 sales guidance.

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) affirms FY2024 Adj EPS guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 analyst estimate. Affirms FY2024 sales outlook from $425.00 million-435.00 million to $425.00 million-435.00 million vs $430.33 million estimate.

FORR

Forrester Res Affirms FY2024 Adj EPS Guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 Est; Affirms FY2024 Sales Guidance from $425.00M-435.00M to $425.00M-435.00M vs $430.33M Est.

Sixth Street Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) reported quarterly earnings of $0.57 per share which met the analyst consensus estimate. This is a 5 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $119.223 million which beat the analyst consensus estimate of $118.508 million by 0.60 percent. This is a 4.18 percent increase over sales of $114.435 million the same period last year.

TSLX

Sixth Street Specialty Q3 2024 Adj. EPS $0.57, Inline, Sales $119.223M Beat $118.508M Estimate

Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) reported quarterly earnings of $0.84 per share. This is a 14.29 percent decrease over earnings of $0.98 per share from the same period last year. The company reported $74.33 million in sales this quarter. This is a 11.67 percent decrease over sales of $84.15 million the same period last year.

WEYS

Weyco Group Q3 EPS $0.84 Down From $0.98 YoY, Sales $74.33M Down From $84.15M YoY

Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) reported quarterly earnings of $1.04 per share which missed the analyst consensus estimate of $1.08 by 3.7 percent. The company reported quarterly sales of $2.92 billion which beat the analyst consensus estimate of $2.83 billion by 3.29 percent. This is a 3.72 percent increase over sales of $2.82 billion the same period last year.

Intl Flavors & Fragrances Q3 2024 Adj EPS $1.04 Misses $1.08 Estimate, Sales $2.92B Beat $2.83B Estimate

Weyco Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) (the "Company") announced that today its Board of Directors declared a special one-time cash dividend of $2.00 per share, for a total of approximately $19.0 million based on the number of shares currently outstanding. The dividend will be paid on January 2, 2025, to shareholders of record at the close of business on November 18, 2024.

Dividends

Weyco Group Declares Special Cash Dividend Of $2.00 Per Share, For A Total Of ~$19M Based On The Number Of Shares Currently Outstanding

Offerings

PLBY

Playboy Announced The Closing Of Its Sale Of 14.9M Newly Issued Shares In A Private Placement At A Price Of $1.50 Per Share For A Total Purchase Price Of $22.35M

SMCI

Super Micro Computer shares are trading lower after the company lowered its financial outlook.

MCHP

Microchip Sees Q3 2024 Adj. EPS $0.29-$0.32

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Tactile Systems Technology (TCMD – Research Report) today and set a price target of $20....

Oppenheimer Remains a Buy on Tactile Systems Technology (TCMD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ginkgo Bioworks Holdings (DNA – Research Report), BioMarin Pharma...

Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), BioMarin Pharmaceutical (BMRN) and Tactile Systems Technology (TCMD)

Every investor hopes to uncover a growth stock, an equity poised for rapid appreciation and substantial long-term returns. The real challenge lies ...

These 2 'Strong Buy' Medical Device Stocks Are Poised for Growth, Says Analyst

Tactile Systems Technology GAAP EPS of $0.21 beats by $0.03, revenue of $73.09M misses by $2.92M

Tactile Systems Technology, Inc. (TCMD) Q3 2024 Earnings Call Transcript

Tactile Systems Technology ( ($TCMD) ) has released its Q3 earnings. Here is a breakdown of the information Tactile Systems Technology presented to...

Tactile Systems Technology Reports Q3 2024 Results, Launches Share Buyback

BTIG downgraded Tactile Systems (TCMD) to Neutral from Buy without a price target following the Q3 report. While the shares are inexpensive and Tac...

Tactile Systems downgraded to Neutral from Buy at BTIG

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Tactile Systems Technology (TCMD – Research Report), with a p...

Piper Sandler Sticks to Their Buy Rating for Tactile Systems Technology (TCMD)

Tactile Systems cut to Neutral at BTIG after Q3 revenue miss

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Boeing's (BA) machinist union ha...

Boeing union to end strike, Palantir reports Q3 beat: Morning Buzz

AAPL

ALAB

AZPN

BMRN

BWIN

CRRFY

CVNA

DLTR

EBAY

EGHT

INFU

JELD

NFLX

NXPI

PAYO

PLTR

QNST

REAL

SLAB

TCMD

UBER

VMEO

Management

Press Releases

Tactile Medical Announces CEO Transition and Preliminary First Quarter 2024 Revenue

Health Care

Tactile Systems Technology, Inc. Reports First Quarter 2024 Financial Results

Tactile Medical to Present at the William Blair 44th Annual Growth Stock Conference

Tactile Medical to Release Second Quarter of Fiscal Year 2024 Financial Results on August 5, 2024

Tactile Systems Technology, Inc. Reports Second Quarter 2024 Financial Results

Tactile Medical Receives PDAC Approval for Nimbl™ Lymphedema Platform

Tactile Medical Announces Positive Clinical Trial Results in Lymphedema Patients Using Advanced Pneumatic Compression Device Therapy

Tactile Medical Launches Next-Generation Nimbl™ Lymphedema Platform

Tactile Medical to Release Third Quarter of Fiscal Year 2024 Financial Results on November 4, 2024

Tactile Systems Technology, Inc. Reports Third Quarter 2024 Financial Results

AngioDynamics

Artivion

Axogen

Butterfly Network, Inc. Class A Common Stock

Butterfly Network

CeriBell

ClearPoint Neuro

CVRx

Delcath Systems

Paragon 28

Inogen

iRadimed

Pulmonx

Nevro

Orchestra BioMed Holdings, Inc. - Ordinary Shares

Orchestra BioMed Hldgs

Orthofix Medical

Pulse Biosciences

Sight Sciences

SI-BONE

Semler Scientific

Surmodics

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts

Varex Imaging

ZimVie

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Jin Medical International

Zynex

B. Riley Securities

Oppenheimer

Piper Sandler

BTIG

Tactile Systems Tech shares are trading lower after BTIG downgraded the stock from Buy to Neutral.

Comments

Tactile Systems Tech

Interés en corto

Tactile Systems Tech (NASDAQ:TCMD) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL